Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
- 31 May 2011
- journal article
- clinical trial
- Published by Elsevier BV in Urology
- Vol. 77 (5), 1166-1171
- https://doi.org/10.1016/j.urology.2011.01.006
Abstract
No abstract availableFunding Information
- Bristol-Myers Squibb
This publication has 29 references indexed in Scilit:
- Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancerAnnals of Oncology, 2010
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2009
- Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II TrialJournal of Urology, 2009
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBritish Journal of Cancer, 2009
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous BisphosphonatesJournal of Clinical Oncology, 2009
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancerSupportive Care in Cancer, 2007
- Osteoblasts in prostate cancer metastasis to boneNature Reviews Cancer, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000